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OBJECTIVE: There are no pharmacoeconomic studies perform
to date comparing voriconazole and liposomal Amphotericin B
(LAB) for the treatment of systemic fungal infections. The aim
of this study was to perform an economic evaluation of voricona-
zole versus LAB for the treatment of invasive aspergillosis and
candidiasis. METHODS: A cost-minimization analysis was per-
formed from the hospital perspective in 2005, as the same efﬁ-
cacy was assumed. A systematic review of available literature
was performed between 1996 and 2005, in order to obtain the
efﬁcacy and incidence of drug-related adverse events (AE) for
each treatment group. Duration of treatment (intravenous: 15.42
days; oral: 4.49 days; the same for both treatments) and mean
weight of patients (68.6Kg) were obtained from a local study:
The Fungcost study (Peiro S. Value Health 2002;5:564). Only
direct costs per episode were considered; medications (iv and
oral) at their hospital selling prices; the cost of monitoring AE;
and administration costs (obtained from a national cost data-
base). Voriconazol was the oral treatment in both groups. The
most important AE for each treatment (and the way to monitor
them) were: hepatotoxicity with voriconazole -13.97%—(two
chemistries and hematologic tests during the treatment period);
and nefrotoxicity with LAB -12.84%—(a daily creatinine clear-
ance measurement). Mean cost per episode and incremental cost
were calculated. RESULTS: Mean cost per episode was €6073.43
(iv treatment 94.22%) for voriconazole, and €8794.33 (iv:
95.78%) for LAB in the treatment of invasive aspergillosis, with
an incremental cost of €2486.90 (28.28%) The treatment of can-
didiasis showed a mean cost of €6307.43 (iv: 94.22%) and
€8779.92 (95.93%), respectively, with an incremental cost of
€2472.48 (28.16%). Results were robust to the sensitivity analy-
sis. CONCLUSION: Using costs and treatment patterns of
fungal infections in Spain, voriconazole is more cost-effective
than LAB for the treatment of invasive candidiasis and
aspergillosis.
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OBJECTIVE: Human Papillomavirus infection is the principal
cause of cervical cancer and most cervical neoplasia. Despite
available screening and treatment, cervical cancer remains an
important public health problem. HPV vaccination studies have
shown high efﬁcacy against HPV-induced cervical lesions. Prior
to implementing a vaccination programme, data about cervical
dysplasia and annual treatment costs are critical. This study
assessed resource use and costs for Pap III, IIID and IV patients
in Germany. METHODS: A one-year retrospective chart review
of 138 patients, diagnosed with Pap III, IIID or IV between Feb-
ruary—March 2004, was conducted to assess clinical and
resource use. Resources included consultations, medications,
procedures, diagnostics, adverse events and hospital stays. Unit
costs from ofﬁcial sources were applied to calculate the average
cost per patient. RESULTS: Most patients had Pap IIID (n = 79)
vs. Pap III (n = 27) or Pap IV (n = 32). Mean duration of treat-
ment was 4.4, 5.5, and 4.9 months for Pap III, IIID and IV
respectively. Pap IIID patients had on average 4.6 gynaecologist
consultations vs. 4.2 and 5.6 for Pap III and IV respectively. Most
common diagnostic tests were Pap-smears (99%) and col-
poscopy (in 89%, 73% and 75% of Pap III, IIID and IV). Typ-
ically, patients were treated by conisation (in 22%, 27% and
84% of Pap III, IIID and IV). More Pap IV patients had hys-
terectomies (22% vs. 4% for Pap III) and laser coagulation
(12.5% vs. 4% for Pap IIID). 33% of the patients were hospi-
talised (mean 7.4 ± 8.3 days). The estimated average annual cost
per patient was €1070, €955 and €3240 for Pap III, IIID and Pap
IV, including 40% indirect costs. CONCLUSION: The cost of
managing pre-cancerous cervical lesions in Germany is high. An
HPV vaccine preventing many of these lesions could avert much
of these costs.
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OBJECTIVE: Human Papillomavirus (HPV) is the main cause
of genital warts (GWs) and a necessary cause of cervical cancer
(CC). There is a lifetime HPV infection risk in women of
55–75%. Genitourinary Medicine (GUM) clinics and CC screen-
ing programmes help in the detection and treatment of GWs and
deceleration of progression to cancerous lesions. This study esti-
mated the annual National Health Service (NHS) costs of diag-
nosing and managing HPV related diseases in a pre-HPV vaccine
era. METHODS: Data for ﬁrst and recurrent GWs episodes were
obtained from the Health Protection Agency and management
pathways from GUM clinicians. The number of women screened
for CC, results, and procedures undertaken for abnormal ﬁnd-
ings were obtained from a variety of sources (e.g., Government
Statistical Service, Regional Screening Programmes; adjusted to
2003). Annual new cases of CC were obtained from GLOBO-
CAN, 2002. Resource costs (2003) included screening tests, clin-
ician visits, diagnostic and treatment procedures, hospital
admissions and drugs. Sensitivity analyses examined the range of
treatment patterns and costs. RESULTS: In 2003, GUM clinics
treated almost 114,000 patients with GWs. Topical creams were
the ﬁrst line treatment for the majority (77%) followed by
cryotherapy or combination of the two. An average 26% of
patients returned to complete their treatment. Total annual costs
for GWs were £22.4 million. In 2003, 4.8 million CC screening
tests were conducted at a cost of £104.5 million. Over 227,209
women were referred for colposcopy, costing £34 million for the
diagnosis and treatment of precancerous lesions. Newly identi-
ﬁed CC cases (N = 3308) and hospital admissions for prevalent
CC cases in 2003 cost £43.7 million. Estimated total 2003 NHS
costs related to HPV were £204.6 million (range: £181.3–£209.7
million). CONCLUSION: Preventing HPV related diseases
through vaccination with a quadrivalent vaccine could result in
cost offsets and more efﬁcient resource allocation.
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OBJECTIVES: Human Papillomavirus (HPV) infections, includ-
ing genital warts (GW), are common. Current treatments are not
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fully satisfactory, a high recurrence rate is observed and preven-
tion strategies are not available. HPV vaccination studies have
shown high efﬁcacy against HPV-induced lesions such as GW.
Before implementing a vaccination programme, data on the inci-
dence and prevalence of GW and their associated treatment costs
are crucial. The objective of this study was to estimate these data.
METHODS: 217 specialists (gynecologists, urologists and der-
matologists) were asked to record the number of patients, aged
14–64yrs, presenting with GW between February and April
2005. The average number of patients per specialist was used to
estimate the annual number of patients. Specialists also con-
ducted a chart review of 189 previously diagnosed GW patients
visiting them in the same period. Resource use, collected from
records going back to February 2004, included visits, diagnos-
tics, medications, procedures and adverse events. The cost of
treating patients with an existing GW diagnosis was calculated
using the average cost per patient and the extrapolated annual
number of existing patients. Indirect costs were included.
RESULTS: It was estimated that there are around 57,000 new
cases and 38,000 existing cases of GW annually in Germany.
Mean treatment duration was 6.7 months, with an average of
3.2 visits to a specialist. 95% of patients had a visual exam, and
the most used diagnostics included Pap smears (25.9%), biop-
sies (25.4%) and colposcopies (24.9%). Most common therapies
were imiquimod (34.4%), electrosurgery (26.5%), laser therapy
(19.1%) and cryotherapy (17.5%). The mean annual treatment
cost per existing patient was €950. The overall estimated treat-
ment costs were €36 million per year; of which €7 million indi-
rect costs. CONCLUSION: The management of GW presents a
high burden to society that could potentially be reduced using a
quadrivalent HPV vaccine.
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OBJECTIVE: New advances in health care have shifted concern
from infectious to chronic illnesses and therefore a new empha-
sis in the assessment of satisfaction with pharmacological treat-
ment has risen. A new generic questionnaire to measure
Satisfaction with medicines is under construction. Item reduction
and factorial validity are discussed here. METHODS: The initial
instrument was composed by 36 items, arranged in 6 dimensions:
1- Efﬁcacy and symptom relieve (5 items), 2- Ease and conve-
nience (6 items), 3- Impact on HRQoL (4 items), 4- Satisfaction
with Medical Care (4 items), 5- Medication Side Effects (8
items), and 6- Overall satisfaction (9 items). Items and dimen-
sions where extracted from review of previous English instru-
ments, a panel compose by 8 experts, and 4 focus groups with
chronic patients. A convenience sample of 156 patients was used,
representative of 7 prevalent chronic pathologies (Diabetes type
II, Hypertension, Osteoarthritis, Prostate problems,
EPOC/Asthma, Depression, and Migraine). Classic psychomet-
ric theory item analysis techniques, exploratory factor analysis,
and conﬁrmatory factor analysis (to estimate accurately factor
correlations) were applied. RESULTS: The questionnaire was
reduced to a new version of 5 dimensions assessed by 14 items,
plus a dimension of Satisfaction with Medication Side Effects (3
items) to be corrected separately due to an important ﬂoor effect.
The reduced version presents an overall Cronbach alpha of
0.881, acceptable goodness of ﬁt indexes, and all factor loadings
are signiﬁcant (p < 0.001). Dimensions are well formed and cor-
relate in different degrees, but the dimension of Satisfaction with
Medical Care shows a relevant relation only with Impact on
HRQoL (r = 0.45). CONCLUSION: The questionnaire shows
good reliability and validity properties. The 5 + 1 proposed
dimensions are stable and well deﬁned in a 17-item form. Results
support that the questionnaire can be used to compute an overall
meaningful score.
PMC2
REVIEW OF THE ACTIVITIES OF THE ISOQOL TRANSLATION
AND CULTURAL ADAPTATION (TCA) SPECIAL INTEREST
GROUP (SIG)
Acquadro C
Mapi Research Trust, Lyon, Rhone, France
The special interest group (SIG) on Translation and Cultural
Adaptation (TCA) had its ﬁrst meeting in Hong Kong at the
2004 Annual ISOQOL meeting. The overall objective of the
TCA SIG is to identify and advance research in different areas
of interest to all parties involved in the ﬁeld of Translation and
Cultural Adaptation. Three priority areas of research were iden-
tiﬁed and organised in three subgroups: translation difﬁculties,
equivalences and methodologies. OBJECTIVES: The objectives
of subgroup one are: 1. To collect, review and analyse examples
of translations difﬁculties in the adaptation of Patient-Reported
Outcomes (PRO) measures; 2. To create a list of “good prac-
tices” for developers of questionnaires and translators, based on
the review of common translation difﬁculties and proposed solu-
tions on how to prevent them. METHODS: The group has
organised its activities in 4 steps: 1. Categorisation of difﬁcul-
ties; 2. Collection of examples of translation difﬁculties; 3.
Review of examples; and 4. Recommendations. RESULTS:
Translation difﬁculties were divided into categories according to:
1. Their position within the PRO questionnaire (i.e. Demo-
graphics, levels of education, “race”, Instructions, Items and
Response Choices); 2.The layout used, e.g. e-layout, tables, font-
related problems; and 3. Their nature: Cultural (Is the construct
to be measured relevant in the target cultures?); Conceptual and
Semantic (Do the items represent the construct deﬁnition?); Syn-
tactic; and Idiomatic. Examples of translation difﬁculties for
each category deﬁned previously and for a selection of families
and branches of languages have been collected and will be pre-
sented. Recommendations on how to prevent potential transla-
tion difﬁculties will be proposed to developers of PRO
questionnaires. CONCLUSIONS: The translation of PRO mea-
sures is a difﬁcult task. “Good practices” for the development
and translation of PRO measures should be implemented to facil-
itate the use of linguistically valid PRO measures in international
research.
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OBJECTIVES: To analyse variation in clinical injury incidence
of 7 European countries, and to determine whether using differ-
ent injury indicators can minimize the bias in clinical injury 
incidence data and increase the comparability of the data.
